Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 3/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428109 | 1.00 | MAOB (0.39) | MAOBSLC1A1FOLH1PPARATSHR | |
| SCHEMBL8059292 | 0.88 | MAOB (0.43) | MAOBSLC1A1FOLH1PPARATSHR | |
| SCHEMBL8068462 | 0.88 | MAOB (0.43) | MAOBSLC1A1FOLH1PPARATSHR | |
| SCHEMBL8068485 | 0.88 | MAOB (0.43) | MAOBSLC1A1FOLH1PPARATSHR | |
| SCHEMBL7594884 | 0.88 | SLC1A1 (0.47) | MAOBSLC1A1FOLH1PPARATSHR | |
| SCHEMBL4938839 | 0.87 | MAOB (0.42) | MAOBSLC1A1FOLH1PPARATSHR | |
| SCHEMBL29406971 | 0.87 | MAOB (0.42) | MAOBSLC1A1FOLH1PPARATSHR | |
| SCHEMBL1144138 | 0.87 | MAOB (0.42) | MAOBSLC1A1FOLH1PPARATSHR | |
| SCHEMBL6428029 | 0.84 | LAP3 (0.43) | LAP3ANPEP | |
| SCHEMBL8059372 | 0.84 | SLC1A1 (0.44) | MAOBSLC1A1FOLH1PPARATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7780952-B2 | Distinguish between tumor cells and normal cells using novel contrast agents that contain a Magnetic Resonance Imaging (MRI) detectable moiety bound, optionally through a spacer, to a (pseudo)nutrient such as glucose, a natural or unnatural amino acid such as agmatine, or a polyamine such as spermidine | BRACCO IMAGING SPA (IT) | 2010-08-24 | — | — | US | claimed |
| EP-1509254-B1 | NEW AGENTS FOR MAGNETIC IMAGING METHOD | BRACCO IMAGING SPA (IT) | 2009-01-14 | — | — | EP | claimed |
| US-20050175543-A1 | Distinguish between tumor cells and normal cells using novel contrast agents that contain a Magnetic Resonance Imaging (MRI) detectable moiety bound, optionally through a spacer, to a (pseudo)nutrient such as glucose, a natural or unnatural amino acid such as agmatine, or a polyamine such as spermidine | BRACCO IMAGING S.P.A. (IT) | 2005-08-11 | — | — | US | claimed |
| EP-1369134-A1 | New agents for magnetic imaging method | Bracco Imaging S.p.A. (IT) | 2003-12-10 | — | — | EP | claimed |
| US-9402924-B2 | Diagnostic compounds for targeting a chemokine receptors | GUERBET (FR) | 2016-08-02 | — | — | US | disclosed |
| US-8926945-B2 | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium | GUERBET (FR) | 2015-01-06 | — | — | US | disclosed |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | GUEREBET (FR) | 2011-04-21 | — | — | US | disclosed |
| EP-1635878-B1 | PEPTIDE CONJUGATE FOR MAGNETIC RESONANCE IMAGING OF MATRIX METALLOPROTEINASES | GUERBET SA (FR) | 2010-12-29 | — | — | EP | disclosed |
| US-7780952-B2 | Distinguish between tumor cells and normal cells using novel contrast agents that contain a Magnetic Resonance Imaging (MRI) detectable moiety bound, optionally through a spacer, to a (pseudo)nutrient such as glucose, a natural or unnatural amino acid such as agmatine, or a polyamine such as spermidine | BRACCO IMAGING SPA (IT) | 2010-08-24 | — | — | US | disclosed |
| EP-1509254-B1 | NEW AGENTS FOR MAGNETIC IMAGING METHOD | BRACCO IMAGING SPA (IT) | 2009-01-14 | — | — | EP | disclosed |
| US-20060239913-A1 | Peptide conjugate for magnetic resonance imaging | GUERBET (FR) | 2006-10-26 | — | — | US | disclosed |
| EP-1635878-A2 | PEPTIDE CONJUGATE FOR MAGNETIC RESONANCE IMAGING | GUERBET (FR) | 2006-03-22 | — | — | EP | disclosed |
| US-20050175543-A1 | Distinguish between tumor cells and normal cells using novel contrast agents that contain a Magnetic Resonance Imaging (MRI) detectable moiety bound, optionally through a spacer, to a (pseudo)nutrient such as glucose, a natural or unnatural amino acid such as agmatine, or a polyamine such as spermidine | BRACCO IMAGING S.P.A. (IT) | 2005-08-11 | — | — | US | disclosed |
| WO-2004112840-A2 | PEPTIDE CONJUGATE FOR MAGNETIC RESONANCE IMAGING | GUERBET (FR) | 2004-12-29 | — | — | WO | disclosed |
| EP-1369134-A1 | New agents for magnetic imaging method | Bracco Imaging S.p.A. (IT) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | KLK3, IGF1R, GIPR | MAOB 3268/4885SLC1A1 3542/4885FOLH1 118/4885 |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | CA5B, CA3, CA1 | MAOB 1720/4885SLC1A1 795/4885FOLH1 17/4885 |
| US-20060239913-A1 | Peptide conjugate for magnetic resonance imaging | MMP11, MMP26, MMP3 | MAOB 1655/4885SLC1A1 1365/4885FOLH1 87/4885 |
| US-20050175543-A1 | Distinguish between tumor cells and normal cells using novel contrast agents that contain a Magnetic Resonance Imaging (MRI) detectable moiety bound, optionally through a spacer, to a (pseudo)nutrient such as glucose, a natural or unnatural amino acid such as agmatine, or a polyamine such as spermidine | SLC7A5, SLC2A9, SLC2A1 | MAOB 4475/4885SLC1A1 34/4885FOLH1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.